Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06954467 | JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 72 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 2, 2025 |
| NCT06978114 | A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer | recruiting | Phase 2 | 46 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07047560 | Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study | recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05310643 | Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC(NIPIRESCUE) | recruiting | Phase 2 | 30 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06895447 | Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07045805 | Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer | not yet recruiting | Phase 2 | 66 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Jul 1, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT04901741 | Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer(OPTIMUS) | not yet recruiting | Phase 2 | 60 | TME Pharma AGINDUSTRY | 0 | Jun 27, 2025 | clinicaltrials |
| NCT05663775 | Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)(IMPACT 1) | recruiting | Phase 2 | 20 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05775146 | SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases | recruiting | Phase 2 | 24 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT02632305 | A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer(AX-CSARC) | active not recruiting | Phase 2 | 45 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05451043 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | recruiting | Phase 2 | 62 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07040098 | Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer(STELLARIII) | recruiting | Phase 2 | 228 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06885385 | A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer | recruiting | Phase 2 | 60 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06057831 | PET/MRI in Rectal Cancer | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 0 | Jun 18, 2025 | clinicaltrials |
| NCT06135896 | Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers(Dulastin) | recruiting | Phase 2 | 98 | National Cancer Center, KoreaOTHER_GOV | 1 | Jun 18, 2025 | clinicaltrials |
| NCT02843945 | Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source | recruiting | Phase 1 / Phase 2 | 80 | CivaTech OncologyINDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06766305 | QL1706 Combined With SOX Used in Theperioperative Treatment | recruiting | Phase 1 / Phase 2 | 54 | Xiangdong ChengOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07025174 | Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer(SAIB) | recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT05118724 | Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin(ANTONIO) | active not recruiting | Phase 2 | 80 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT07021950 | AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 130 | Sun Yat-sen UniversityOTHER | 0 | Jun 15, 2025 | clinicaltrials |
| NCT04730544 | Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.(NIPISAFE) | active not recruiting | Phase 2 | 96 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06646445 | Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.(PREMICES) | not yet recruiting | Phase 2 | 60 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07019181 | Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma | not yet recruiting | Phase 2 | 26 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT05771181 | Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07016724 | Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer | recruiting | Phase 2 | 208 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07018063 | Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer(YOUNG-NEOS) | not yet recruiting | Phase 2 | 35 | zhoujingOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02678182 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial(PLATFORM) | active not recruiting | Phase 2 | 494 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06446726 | Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Sichuan UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07007728 | Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis | not yet recruiting | Phase 2 | 54 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07009145 | QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC | not yet recruiting | Phase 2 | 22 | Qianfoshan HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT04581473 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | active not recruiting | Phase 1 / Phase 2 | 192 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05241249 | Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma | recruiting | Phase 2 | 37 | Susan E. BatesOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06999707 | Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC(Photon-STRIDE) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT07003815 | Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 62 | Tongji HospitalOTHER | 0 | Jun 4, 2025 | clinicaltrials |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | AkesoINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07000305 | A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer(SUPβORT) | not yet recruiting | Phase 2 | 42 | Tao ZhangOTHER | 1 | Jun 2, 2025 | clinicaltrials |
| NCT06944106 | A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06998771 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | not yet recruiting | Phase 2 | 153 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT06999252 | Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients | not yet recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06999512 | Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer(HPB70+) | not yet recruiting | Phase 2 / Phase 3 | 526 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT02340117 | Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 28 | SynerGene Therapeutics, Inc.INDUSTRY | 1 | May 30, 2025 | clinicaltrials |
| NCT04084496 | mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT05201352 | Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine(TASKIN) | active not recruiting | Phase 1 / Phase 2 | 160 | Centre Georges Francois LeclercOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06157996 | Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore | recruiting | Phase 2 | 92 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06421376 | Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer | recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT05908643 | A First-In-Human Trial of pTTL in Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 16 | Neogap Therapeutics ABINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jul 2, 2025source: clinicaltrials